Efficacy of Pegylated Interferon on Liver Fibrosis in Co-infected Patient With HIV and Hepatitis C
HIV Infections, Hepatitis C, Chronic
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring HIV infections, peginterferon alfa-2a, Treatment Failure, Hepatitis C, Chronic, Treatment Experienced
Eligibility Criteria
Inclusion Criteria: HIV infection (Western Blot +) C hepatitis (RNA viral hepatitis C [VHC] +) Chronic active C hepatitis on liver histological score METAVIR (A over or equal to 1 and F over or equal to 2) on biopsy performed at least 18 months before the expected date of inclusion Previous treatment for C hepatitis for at least 3 months including peg-interferon and ribavirin or peg-interferon alone if counterindication for ribavirin occurred Failure to eradicate C hepatitis virus after well conducted treatment The liver biopsy should have been realised at least 18 months before inclusion : Either before treatment for C hepatitis in patients treated at most 7 months Or at least 6 months after anti HCV treatment in patient treated for more than 7 months (wash out period) Regular follow up in an outpatient clinic for HIV Unchanged antiretroviral treatment the last 3 months before inclusion Inform consent Exclusion Criteria: History of transplantation or clinical hepatic failure Opportunistic infection in the past three months before inclusion Any hepatic disease not related to HCV (B hepatitis, hemochromatosis, Wilson disease) Diabetes mellitus Immunocompromised treatment Active intravenous drug addiction Alcohol consumption of more than 50 g per day Counterindication for the use of interferon
Sites / Locations
- Service de Maladies Infectieuses et de Réanimation Médicale
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Peginterféron alpha-2a + Ribavirin+ HIV antiretroviral therapy
HIV antiretroviral therapy
Day0 to week 96:Peginterféron alpha-2a + Ribavirin+ HIV antiretroviral therapy
Day0 to week 96: HIV antiretroviral therapy